Loading...

Daryl L Davies, PhD

Title(s)Professor Of Clinical Pharmacy and Director of Undergraduate Education
Phone+1 323 442 1427
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Daryl L. Davies, PhD, Professor of Clinical Pharmacy, Titus Family Department of Clinical Pharmacy, University of Southern California. In addition, he is the Director of the MS program in Management of Drug Development, in the International Center of Regulatory Science located in the School of Pharmacy. Dr. Davies earned his Bachelor and Master Degrees in Biology at California State University, Dominguez Hills. He earned his PhD in 1996 from the Department of Molecular Pharmacology and Toxicology at USC School of Pharmacy.
    Dr. Davies is the director of the Alcohol and Brain Research Laboratory at USC. His research revolves around the development of novel treatments for alcohol use disorders (AUDs). AUDs ranks third on the list of preventable causes of morbidity and mortality in the United States, having a major national impact affecting over 18 million people and causing over 100,000 deaths annually. The economic burden to society for AUDs is in excess of $220 billion annually which exceeds the costs of other leading preventable causes of death such as cigarette smoking and physical inactivity. Presently, pharmacotherapies, even in conjunction with psychosocial strategies, have had limited success in treating AUDs with approximately 70% of patients relapsing back into heavy drinking within one year. Finally, drug development for AUDs is a relatively young field compared to other diseases such as cancer, cardiovascular and psychiatric disorders. Therefore, the development of new treatments for AUDs represents an important unmet medical need.
    In response to this challenge, Dr. Davies and his team have focused on identifying molecular targets of alcohol action in the CNS. Recent findings from this line of investigation have resulted in the identification of specific targets for which therapeutic compounds have been designed and are currently under investigation. This multidisciplinary endeavor has brought together diverse but complementary group of scientists which include behavioral, pharmacological, electrophysiological, molecular, genetic, computational and medicinal chemistry expertise’s to maximize the potential for success. This team includes Drs. Ronald Alkana and Stan Louie (School of Pharmacy), Dr. Michael Neely (Keck School of Medicine), Dr. Nicos Petasis (Dornsife College LAS), Dr. Debra Finn (Oregon Health & Science University), and Dr. James Trudell (Stanford).

    Collapse Research 
    Collapse Research Activities and Funding
    Regulation of Alcohol Intake by Purinergic P2X4 Receptors
    NIH/NIAAA R01AA022448Sep 1, 2013 - Jun 30, 2021
    Role: Principal Investigator
    Sites and Mechanisms of Ethanol Action in P2X receptors
    NIH/NIAAA R01AA013922Aug 15, 2004 - May 31, 2010
    Role: Principal Investigator
    Pressure-Based Pharmacological Alcoholism Treatments
    NIH/NIAAA R21AA013890May 1, 2003 - Apr 30, 2008
    Role: Principal Investigator
    GABA ALLOSTERIC PATHWAYS AND SITES OF ETHANOL ACTION
    NIH/NIAAA F31AA005436Mar 27, 1996
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Khoja S, Asatryan L, Jakowec MW, Davies DL. Dopamine Receptor Blockade Attenuates Purinergic P2X4 Receptor-Mediated Prepulse Inhibition Deficits and Underlying Molecular Mechanisms. Front Cell Neurosci. 2019; 13:331. PMID: 31396053.
      View in: PubMed
    2. Cayla NS, Dagne BA, Wu Y, Lu Y, Rodriguez L, Davies DL, Gross ER, Heifets BD, Davies MF, MacIver MB, Bertaccini EJ. A newly developed anesthetic based on a unique chemical core. Proc Natl Acad Sci U S A. 2019 Jul 30; 116(31):15706-15715. PMID: 31308218.
      View in: PubMed
    3. Getachew B, Reyes RE, Davies DL, Tizabi Y. Moxidectin Effects on Gut Microbiota of Wistar-Kyoto Rats: Relevance to Depressive-Like Behavior. Clin Pharmacol Transl Med. 2019; 3(1):134-142. PMID: 31321385.
      View in: PubMed
    4. Huynh N, Arabian NM, Asatryan L, Davies DL. Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice. J Vis Exp. 2019 01 07; (143). PMID: 30663649.
      View in: PubMed
    5. Freire D, Reyes RE, Baghram A, Davies DL, Asatryan L. P2X7 Receptor Antagonist A804598 Inhibits Inflammation in Brain and Liver in C57BL/6J Mice Exposed to Chronic Ethanol and High Fat Diet. J Neuroimmune Pharmacol. 2019 Jun; 14(2):263-277. PMID: 30353422.
      View in: PubMed
    6. Csóka B, Németh ZH, Szabó I, Davies DL, Varga ZV, Pálóczi J, Falzoni S, Di Virgilio F, Muramatsu R, Yamashita T, Pacher P, Haskó G. Macrophage P2X4 receptors augment bacterial killing and protect against sepsis. JCI Insight. 2018 06 07; 3(11). PMID: 29875325.
      View in: PubMed
    7. Khoja S, Huynh N, Warnecke AMP, Asatryan L, Jakowec MW, Davies DL. Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders. Psychopharmacology (Berl). 2018 06; 235(6):1697-1709. PMID: 29500584.
      View in: PubMed
    8. Khoja S, Huynh N, Asatryan L, Jakowec MW, Davies DL. Reduced expression of purinergic P2X4 receptors increases voluntary ethanol intake in C57BL/6J mice. Alcohol. 2018 05; 68:63-70. PMID: 29477921.
      View in: PubMed
    9. Asatryan L, Ostrovskaya O, Lieu D, Davies DL. Ethanol differentially modulates P2X4 and P2X7 receptor activity and function in BV2 microglial cells. Neuropharmacology. 2018 Jan; 128:11-21. PMID: 28943285.
      View in: PubMed
    10. Lindemeyer AK, Shen Y, Yazdani F, Shao XM, Spigelman I, Davies DL, Olsen RW, Liang J. a2 Subunit-Containing GABAA Receptor Subtypes Are Upregulated and Contribute to Alcohol-Induced Functional Plasticity in the Rat Hippocampus. Mol Pharmacol. 2017 08; 92(2):101-112. PMID: 28536106.
      View in: PubMed
    11. Huynh N, Arabian N, Naito A, Louie S, Jakowec MW, Asatryan L, Davies DL. Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder. Neuropharmacology. 2017 02; 113(Pt A):60-70. PMID: 27641072.
      View in: PubMed
    12. Xu J, Bernstein AM, Wong A, Lu XH, Khoja S, Yang XW, Davies DL, Micevych P, Sofroniew MV, Khakh BS. P2X4 Receptor Reporter Mice: Sparse Brain Expression and Feeding-Related Presynaptic Facilitation in the Arcuate Nucleus. J Neurosci. 2016 08 24; 36(34):8902-20. PMID: 27559172.
      View in: PubMed
    13. Khoja S, Shah V, Garcia D, Asatryan L, Jakowec MW, Davies DL. Role of purinergic P2X4 receptors in regulating striatal dopamine homeostasis and dependent behaviors. J Neurochem. 2016 10; 139(1):134-48. PMID: 27402173.
      View in: PubMed
    14. Guizzetti M, Davies DL, Egli M, Finn DA, Molina P, Regunathan S, Robinson DL, Sohrabji F. Sex and the Lab: An Alcohol-Focused Commentary on the NIH Initiative to Balance Sex in Cell and Animal Studies. Alcohol Clin Exp Res. 2016 06; 40(6):1182-91. PMID: 27154003.
      View in: PubMed
    15. Roche DJ, Yardley MM, Lunny KF, Louie SG, Davies DL, Miotto K, Ray LA. A Pilot Study of the Safety and Initial Efficacy of Ivermectin for the Treatment of Alcohol Use Disorder. Alcohol Clin Exp Res. 2016 06; 40(6):1312-20. PMID: 27087145.
      View in: PubMed
    16. Huynh N, Arabian N, Lieu D, Asatryan L, Davies DL. Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals. J Vis Exp. 2016 Mar 23; (109):e53770. PMID: 27078261.
      View in: PubMed
    17. Asatryan L, Khoja S, Rodgers KE, Alkana RL, Tsukamoto H, Davies DL. Chronic ethanol exposure combined with high fat diet up-regulates P2X7 receptors that parallels neuroinflammation and neuronal loss in C57BL/6J mice. J Neuroimmunol. 2015 Aug 15; 285:169-79. PMID: 26198936.
      View in: PubMed
    18. Yardley MM, Huynh N, Rodgers KE, Alkana RL, Davies DL. Oral delivery of ivermectin using a fast dissolving oral film: Implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder. Alcohol. 2015 Sep; 49(6):553-9. PMID: 26095588.
      View in: PubMed
    19. Helms CM, Bell RL, Bennett AJ, Davies DL, Chester JA, Kosten TA, Leeman RF, Panicker S, Platt DM, Weiner JL, Edwards S. The importance of animals in advancing research on alcohol use disorders. Alcohol Clin Exp Res. 2015 Apr; 39(4):575-8. PMID: 25833015.
      View in: PubMed
    20. Naito A, Muchhala KH, Trang J, Asatryan L, Trudell JR, Homanics GE, Alkana RL, Davies DL. Manipulations of extracellular Loop 2 in a1 GlyR ultra-sensitive ethanol receptors (USERs) enhance receptor sensitivity to isoflurane, ethanol, and lidocaine, but not propofol. Neuroscience. 2015 Jun 25; 297:68-77. PMID: 25827497.
      View in: PubMed
    21. Naito A, Muchhala KH, Asatryan L, Trudell JR, Homanics GE, Perkins DI, Davies DL, Alkana RL. Glycine and GABA(A) ultra-sensitive ethanol receptors as novel tools for alcohol and brain research. Mol Pharmacol. 2014 Dec; 86(6):635-46. PMID: 25245406.
      View in: PubMed
    22. Yardley MM, Neely M, Huynh N, Asatryan L, Louie SG, Alkana RL, Davies DL. Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans. Neuroreport. 2014 Sep 10; 25(13):1018-23. PMID: 25004078.
      View in: PubMed
    23. Franklin KM, Asatryan L, Jakowec MW, Trudell JR, Bell RL, Davies DL. P2X4 receptors (P2X4Rs) represent a novel target for the development of drugs to prevent and/or treat alcohol use disorders. Front Neurosci. 2014; 8:176. PMID: 25009459.
      View in: PubMed
    24. Wyatt LR, Finn DA, Khoja S, Yardley MM, Asatryan L, Alkana RL, Davies DL. Contribution of P2X4 receptors to ethanol intake in male C57BL/6 mice. Neurochem Res. 2014 Jun; 39(6):1127-39. PMID: 24671605.
      View in: PubMed
    25. Asatryan L, Yardley MM, Khoja S, Trudell JR, Hyunh N, Louie SG, Petasis NA, Alkana RL, Davies DL. Avermectins differentially affect ethanol intake and receptor function: implications for developing new therapeutics for alcohol use disorders. Int J Neuropsychopharmacol. 2014 Jun; 17(6):907-16. PMID: 24451653.
      View in: PubMed
    26. Olsen RW, Li GD, Wallner M, Trudell JR, Bertaccini EJ, Lindahl E, Miller KW, Alkana RL, Davies DL. Structural models of ligand-gated ion channels: sites of action for anesthetics and ethanol. Alcohol Clin Exp Res. 2014 Mar; 38(3):595-603. PMID: 24164436.
      View in: PubMed
    27. Popova M, Trudell J, Li K, Alkana R, Davies D, Asatryan L. Tryptophan 46 is a site for ethanol and ivermectin action in P2X4 receptors. Purinergic Signal. 2013 Dec; 9(4):621-32. PMID: 23817978.
      View in: PubMed
    28. Wyatt LR, Godar SC, Khoja S, Jakowec MW, Alkana RL, Bortolato M, Davies DL. Sociocommunicative and sensorimotor impairments in male P2X4-deficient mice. Neuropsychopharmacology. 2013 Sep; 38(10):1993-2002. PMID: 23604007.
      View in: PubMed
    29. Bortolato M, Yardley MM, Khoja S, Godar SC, Asatryan L, Finn DA, Alkana RL, Louie SG, Davies DL. Pharmacological insights into the role of P2X4 receptors in behavioural regulation: lessons from ivermectin. Int J Neuropsychopharmacol. 2013 Jun; 16(5):1059-70. PMID: 23174033.
      View in: PubMed
    30. Davies DL, Bortolato M, Finn DA, Ramaker MJ, Barak S, Ron D, Liang J, Olsen RW. Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders. Alcohol Clin Exp Res. 2013 Jan; 37(1):8-15. PMID: 22671690.
      View in: PubMed
    31. Yardley MM, Wyatt L, Khoja S, Asatryan L, Ramaker MJ, Finn DA, Alkana RL, Huynh N, Louie SG, Petasis NA, Bortolato M, Davies DL. Ivermectin reduces alcohol intake and preference in mice. Neuropharmacology. 2012 Aug; 63(2):190-201. PMID: 22465817.
      View in: PubMed
    32. Perkins DI, Trudell JR, Asatryan L, Davies DL, Alkana RL. Charge and geometry of residues in the loop 2 ß hairpin differentially affect agonist and ethanol sensitivity in glycine receptors. J Pharmacol Exp Ther. 2012 May; 341(2):543-51. PMID: 22357974.
      View in: PubMed
    33. Howard RJ, Slesinger PA, Davies DL, Das J, Trudell JR, Harris RA. Alcohol-binding sites in distinct brain proteins: the quest for atomic level resolution. Alcohol Clin Exp Res. 2011 Sep; 35(9):1561-73. PMID: 21676006.
      View in: PubMed
    34. Asatryan L, Nam HW, Lee MR, Thakkar MM, Saeed Dar M, Davies DL, Choi DS. Implication of the purinergic system in alcohol use disorders. Alcohol Clin Exp Res. 2011 Apr; 35(4):584-94. PMID: 21223299.
      View in: PubMed
    35. Ostrovskaya O, Asatryan L, Wyatt L, Popova M, Li K, Peoples RW, Alkana RL, Davies DL. Ethanol is a fast channel inhibitor of P2X4 receptors. J Pharmacol Exp Ther. 2011 Apr; 337(1):171-9. PMID: 21212160.
      View in: PubMed
    36. Xu L, Li Y, Haworth IS, Davies DL. Functional role of the intracellular loop linking transmembrane domains 6 and 7 of the human dipeptide transporter hPEPT1. J Membr Biol. 2010 Dec; 238(1-3):43-9. PMID: 21104182.
      View in: PubMed
    37. Asatryan L, Popova M, Perkins D, Trudell JR, Alkana RL, Davies DL. Ivermectin antagonizes ethanol inhibition in purinergic P2X4 receptors. J Pharmacol Exp Ther. 2010 Sep 01; 334(3):720-8. PMID: 20543096.
      View in: PubMed
    38. Perkins DI, Trudell JR, Crawford DK, Alkana RL, Davies DL. Molecular targets and mechanisms for ethanol action in glycine receptors. Pharmacol Ther. 2010 Jul; 127(1):53-65. PMID: 20399807.
      View in: PubMed
    39. Popova M, Asatryan L, Ostrovskaya O, Wyatt LR, Li K, Alkana RL, Davies DL. A point mutation in the ectodomain-transmembrane 2 interface eliminates the inhibitory effects of ethanol in P2X4 receptors. J Neurochem. 2010 Jan; 112(1):307-17. PMID: 19878433.
      View in: PubMed
    40. Xu L, Haworth IS, Kulkarni AA, Bolger MB, Davies DL. Mutagenesis and cysteine scanning of transmembrane domain 10 of the human dipeptide transporter. Pharm Res. 2009 Oct; 26(10):2358-66. PMID: 19685173.
      View in: PubMed
    41. Perkins DI, Trudell JR, Crawford DK, Asatryan L, Alkana RL, Davies DL. Loop 2 structure in glycine and GABA(A) receptors plays a key role in determining ethanol sensitivity. J Biol Chem. 2009 Oct 02; 284(40):27304-14. PMID: 19656948.
      View in: PubMed
    42. Crawford DK, Perkins DI, Trudell JR, Bertaccini EJ, Davies DL, Alkana RL. Roles for loop 2 residues of alpha1 glycine receptors in agonist activation. J Biol Chem. 2008 Oct 10; 283(41):27698-706. PMID: 18658152.
      View in: PubMed
    43. Asatryan L, Popova M, Woodward JJ, King BF, Alkana RL, Davies DL. Roles of ectodomain and transmembrane regions in ethanol and agonist action in purinergic P2X2 and P2X3 receptors. Neuropharmacology. 2008 Oct; 55(5):835-43. PMID: 18639563.
      View in: PubMed
    44. Xiao C, Zhou C, Li K, Davies DL, Ye JH. Purinergic type 2 receptors at GABAergic synapses on ventral tegmental area dopamine neurons are targets for ethanol action. J Pharmacol Exp Ther. 2008 Oct; 327(1):196-205. PMID: 18583548.
      View in: PubMed
    45. Perkins DI, Trudell JR, Crawford DK, Alkana RL, Davies DL. Targets for ethanol action and antagonism in loop 2 of the extracellular domain of glycine receptors. J Neurochem. 2008 Aug; 106(3):1337-49. PMID: 18485105.
      View in: PubMed
    46. Li K, Xu L, Kulkarni AA, Perkins DI, Haworth IS, Davies DL. Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May; 32(5):777-84. PMID: 18336632.
      View in: PubMed
    47. Crawford DK, Trudell JR, Bertaccini EJ, Li K, Davies DL, Alkana RL. Evidence that ethanol acts on a target in Loop 2 of the extracellular domain of alpha1 glycine receptors. J Neurochem. 2007 Sep; 102(6):2097-2109. PMID: 17561937.
      View in: PubMed
    48. Links JL, Kulkarni AA, Davies DL, Lee VH, Haworth IS. Cysteine scanning of transmembrane domain three of the human dipeptide transporter: implications for substrate transport. J Drug Target. 2007 Apr; 15(3):218-25. PMID: 17454359.
      View in: PubMed
    49. Kulkarni AA, Davies DL, Links JS, Patel LN, Lee VH, Haworth IS. A charge pair interaction between Arg282 in transmembrane segment 7 and Asp341 in transmembrane segment 8 of hPepT1. Pharm Res. 2007 Jan; 24(1):66-72. PMID: 17009102.
      View in: PubMed
    50. Davies DL, Asatryan L, Kuo ST, Woodward JJ, King BF, Alkana RL, Xiao C, Ye JH, Sun H, Zhang L, Hu XQ, Hayrapetyan V, Lovinger DM, Machu TK. Effects of ethanol on adenosine 5'-triphosphate-gated purinergic and 5-hydroxytryptamine receptors. Alcohol Clin Exp Res. 2006 Feb; 30(2):349-58. PMID: 16441284.
      View in: PubMed
    51. Davies DL, Kuo ST, Alkana RL. Differential effects of propofol and ethanol on P2X4 receptors expressed in Xenopus oocytes. Int Congr Ser. 2005 Nov; 1283:285-287. PMID: 16570112.
      View in: PubMed
    52. Davies DL, Kochegarov AA, Kuo ST, Kulkarni AA, Woodward JJ, King BF, Alkana RL. Ethanol differentially affects ATP-gated P2X(3) and P2X(4) receptor subtypes expressed in Xenopus oocytes. Neuropharmacology. 2005 Aug; 49(2):243-53. PMID: 15993446.
      View in: PubMed
    53. Woodward JJ, Nowak M, Davies DL. Effects of the abused solvent toluene on recombinant P2X receptors expressed in HEK293 cells. Brain Res Mol Brain Res. 2004 Jun 18; 125(1-2):86-95. PMID: 15193425.
      View in: PubMed
    54. Davies DL, Crawford DK, Trudell JR, Mihic SJ, Alkana RL. Multiple sites of ethanol action in alpha1 and alpha2 glycine receptors suggested by sensitivity to pressure antagonism. J Neurochem. 2004 Jun; 89(5):1175-85. PMID: 15147510.
      View in: PubMed
    55. Uchiyama T, Kulkarni AA, Davies DL, Lee VH. Biophysical evidence for His57 as a proton-binding site in the mammalian intestinal transporter hPepT1. Pharm Res. 2003 Dec; 20(12):1911-6. PMID: 14725353.
      View in: PubMed
    56. Davies DL, Alkana RL. Benzodiazepine agonist and inverse agonist coupling in GABAA receptors antagonized by increased atmospheric pressure. Eur J Pharmacol. 2003 May 23; 469(1-3):37-45. PMID: 12782183.
      View in: PubMed
    57. Davies DL, Trudell JR, Mihic SJ, Crawford DK, Alkana RL. Ethanol potentiation of glycine receptors expressed in Xenopus oocytes antagonized by increased atmospheric pressure. Alcohol Clin Exp Res. 2003 May; 27(5):743-55. PMID: 12766618.
      View in: PubMed
    58. Davies DL, Machu TK, Guo Y, Alkana RL. Ethanol sensitivity in ATP-gated P2X receptors is subunit dependent. Alcohol Clin Exp Res. 2002 Jun; 26(6):773-8. PMID: 12068244.
      View in: PubMed
    59. Davies DL, McCauley LD, Bolger MB, Alkana RL. Pressure-sensitive and -insensitive coupling in gamma-aminobutyric acid(A) receptors. Psychopharmacology (Berl). 2001 Oct; 157(4):401-10. PMID: 11605100.
      View in: PubMed
    60. Davies DL, Alkana RL. Direct evidence for a cause-effect link between ethanol potentiation of GABA(A) receptor function and intoxication from hyperbaric studies in C57, LS, and SS mice. Alcohol Clin Exp Res. 2001 Aug; 25(8):1098-106. PMID: 11505039.
      View in: PubMed
    61. Davies DL, Alkana RL. Ethanol enhances GABAA receptor function in short sleep and long sleep mouse brain membranes. Alcohol Clin Exp Res. 2001 Mar; 25(3):478-83. PMID: 11290862.
      View in: PubMed
    62. Ladner CJ, Babbini M, Davies DL, Parker ES, Alkana RL. Effects of posttraining ethanol on an appetitive task. Neurobiol Learn Mem. 2001 Jan; 75(1):111-20. PMID: 11124050.
      View in: PubMed
    63. Davies DL, Bolger MB, Brinton RD, Finn DA, Alkana RL. In vivo and in vitro hyperbaric studies in mice suggest novel sites of action for ethanol. Psychopharmacology (Berl). 1999 Feb; 141(4):339-50. PMID: 10090641.
      View in: PubMed
    64. Davies DL, Alkana RL. Direct antagonism of ethanol's effects on GABA(A) receptors by increased atmospheric pressure. Alcohol Clin Exp Res. 1998 Nov; 22(8):1689-97. PMID: 9835282.
      View in: PubMed
    65. Syapin PJ, Jones BL, Finn DA, Davies DL, Alkana RL. Effect of 12 atmospheres helium-oxygen on the response of mice to convulsant drugs. Undersea Hyperb Med. 1996 Mar; 23(1):35-41. PMID: 8653064.
      View in: PubMed
    66. Davies DL, Bejanian M, Parker ES, Mørland J, Bolger MB, Brinton RD, Alkana RL. Low level hyperbaric antagonism of diazepam's locomotor depressant and anticonvulsant properties in mice. J Pharmacol Exp Ther. 1996 Feb; 276(2):667-75. PMID: 8632335.
      View in: PubMed
    67. Alkana RL, Davies DL, Mørland J, Parker ES, Bejanian M. Low-level hyperbaric exposure antagonizes locomotor effects of ethanol and n-propanol but not morphine in C57BL mice. Alcohol Clin Exp Res. 1995 Jun; 19(3):693-700. PMID: 7573795.
      View in: PubMed
    68. Davies DL, Mørland J, Jones BL, Alkana RL. Low-level hyperbaric antagonism of ethanol's anticonvulsant property in C57BL/6J mice. Alcohol Clin Exp Res. 1994 Oct; 18(5):1190-5. PMID: 7847605.
      View in: PubMed